Interview with Maria Flynn, Adare Pharmaceuticals

As President and Chief Executive Officer of Orbis Biosciences, Maria Flynn led a company that provides innovative technology that improves the delivery, efficacy, and safety of pharmaceuticals Under her leadership, the Convention on Pharmaceutical Ingredients awarded Orbis the Excellence in Formulation Award and, in 2020, Adare Pharmaceuticals acquired the company Previously, Ms Flynn was a Director at Cerner Corporation (North Kansas City, MO, US) and, before that, an engineer with Camp Dresser & McKee (now CDM Smith, Boston, MA, US) Ms Flynn has been named in Entrepreneur Magazine’s “Entrepreneurial Women to Watch”, Kansas City Business Journal’s “Women Who Mean Business”, and Ingram’s “Business Magazine’s 40 Under 40”, and she received the Central Exchange’s “STEMMy Award for Enterprising Innovator” She serves on the Board of Directors of BioNexus KC (DBA Kansas City Area Life Sciences Institute), and she is a member of Pipeline Entrepreneurs, the region’s premier entrepreneurial leadership organisation Ms Flynn holds an MBA from the University of Chicago Booth School of Business, where she was a Herman Family Fellow for Women in Entrepreneurship, an MS in engineering from Stanford University, and a BS in engineering from Kansas State University Maria Flynn talks with ONdrugDelivery about trends in the oral drug development and delivery space, completing the Orbis acquisition during a global pandemic, and how the excellent technology portfolio and strategic fit between Orbis and Adare form part of the combined organisation’s unique story